How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain

Naxitamab [humanized 3f8 (hu3F8)] is a humanized monoclonal antibody (mAb) targeting the disialoganglioside GD2. It was approved in 2020 by the United States Food and Drug Administration (FDA) in combination with granulocyte–macrophage colony-stimulating factor (GM-CSF) for treatment of pediatric an...

Descripción completa

Detalles Bibliográficos
Autores principales: Castañeda, A., Gorostegui, M., Miralles, S.L., Chamizo, A., Patiño, S.C., Flores, M.A., Garraus, M., Lazaro, J.J., Santa-Maria, V., Varo, A., Muñoz, J.P., Mora, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006652/
https://www.ncbi.nlm.nih.gov/pubmed/35397431
http://dx.doi.org/10.1016/j.esmoop.2022.100462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006652/
https://www.ncbi.nlm.nih.gov/pubmed/35397431
http://dx.doi.org/10.1016/j.esmoop.2022.100462

Ejemplares similares